Quotient Sciences Expands Formulation Development Capabilities to Further Accelerate Drug Development Timelines

In February 2023, Quotient Sciences, the drug development and manufacturing accelerator, issued a press release announcing the completion of a laboratory expansion at its Nottingham, UK, facility to support early-phase formulation development capabilities for oral dosage forms. The investment expanded Quotient Sciences’ high-containment laboratory capacity to support immediate-release and modified-release tablet and multi-particulate dosage forms for highly potent compounds. The expanded services build upon Quotient Sciences’ existing formulation capabilities at the site and increase the company’s overall capacity to support fully integrated Translational Pharmaceutics® programs.

As Andy Lewis, Global Vice President of Integrated Pharmaceutical Sciences at Quotient Sciences, shared in the press release, “With these expanded capabilities, we can start formulation development work even earlier for our customers, allowing for projects to start faster and turnaround times to be reduced, which in turn will speed up development timelines. Importantly, the new equipment and process trains are fully integrated with our existing capabilities, so at the appropriate point we can quickly transition drug programs downstream into GMP clinical trial manufacturing, saving our customers precious time in advancing innovative medicines into the clinic.”

Read the full press release here: https://www.quotientsciences.com/news/nottingham-expands-formulation-development/